Aligos Therapeutics company information, Employees & Contact Information

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference Yahoo Finance

Oct 21-22: Aligos Therapeutics to Present at H.C. Wainwright Liver Disease Conference — webcast, 30-day replay Stock Titan

Aligos Therapeutics Announces Adoption of Pevifoscorvir Sodium as Nonproprietary Name for ALG-000184 in Chronic Hepatitis B Treatment Quiver Quantitative

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025 Investing News Network

Oklahoma City News - The Oklahoman FinancialContent

27,400-Share Grant: Aligos Grants Stock Options Vesting Over 4-Year Schedule for New Hires Stock Titan

Aligos Therapeutics, Inc. Announces Eight Presentations at The Liver Meeting® 2025, Including Oral Presentation on Novel HBV Therapy Quiver Quantitative

pevifoscorvir sodium: Aligos Therapeutics' ALG-000184 gets USAN adoption; Phase 2 B-Supreme ongoing Stock Titan

Aligos Therapeutics, Inc. to Announce Second Quarter 2025 Financial Results on August 6, 2025 Quiver Quantitative

8 Abstracts Accepted — Aligos Presents Oral 96‑Week ALG-000184 HBV Data at The Liver Meeting 2025 Stock Titan

Aligos Therapeutics Reports Second Quarter 2025 Financial Results and Progress on Clinical Studies Quiver Quantitative

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection Yahoo Finance

Clinical-Stage Liver Disease Developer Aligos Therapeutics to Share Updates at Global Investment Conference Stock Titan

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC) Yahoo Finance

42,300 Shares: Aligos Therapeutics Awards New Employee Stock Options with 4-Year Vesting Stock Titan

Breakthrough HBV Drug Shows Direct cccDNA Reduction: Aligos Therapeutics Unveils Game-Changing Results Stock Titan

Aligos Therapeutics Appoints Ramón Polo as Senior VP, Head of Global Regulatory Affairs Quiver Quantitative

Former J&J COVID-19 Vaccine Regulatory Leader Joins Aligos Therapeutics as Global Regulatory Head Stock Titan

Aligos Reports Breakthrough HBV Drug Results: 100% Patient Response in Phase 1 as Pivotal Trial Launches Stock Titan

Major Funding Alert: Aligos Lands $105M Investment for Game-Changing Hepatitis B Drug Development Stock Titan

The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075 | Journal of Medicinal Chemistry ACS Publications

Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH) 2 Minute Medicine

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 Investing News Network

Phase II B-SUPREME Trial Launches for ALG-000184 in Chronic Hepatitis B Applied Clinical Trials

HERALD: ALG-055009 Demonstrates Liver Fat Reduction in Phase 2a MASH Study HCPLive

Discovery and Preclinical Profile of ALG-097558, a Pan-Coronavirus 3CLpro Inhibitor ACS Publications

Aligos' MASH prospect slashes liver fat in phase 2, but stock drops anyway Fierce Biotech

Aligos Therapeutics: Promising Pipeline With Cash And Dilution Risks (NASDAQ:ALGS) Seeking Alpha

Aligos Therapeutics and KU Leuven Announce Collaboration GlobeNewswire

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024 FinancialContent

Aligos Therapeutics Closes $125M Series B Financing GlobeNewswire

ALGS - Aligos Therapeutics, Inc. Latest Stock News & Market Updates Stock Titan

Aligos Therapeutics Presents Strong Chronic Hepatitis B Drug Candidate Portfolio at The Liver Meeting® 2019 GlobeNewswire